- Hypertension affects nearly half of all adults in the United States – 47% or 116 million people, some of which are medication-resistant
- A recent study from the University of Toledo College of Medicine and Life Sciences concluded gut bacteria might be the cause of medication-resistant hypertension – as demonstrated in rats used to conduct the study
- Lexaria’s patented DehydraTECH(TM) technology offers a viable solution for hypertension drug administration and has been received favorably by the FDA during a pre-Investigational New Drug meeting
Hypertension, or high blood pressure, remains one of the world’s most deadly health problems, considered a silent killer because it presents with no symptoms. Nearly half of the adult population in the United States (47% or 116 million) have been diagnosed with hypertension, as defined by having systolic blood pressure greater than 130 mmHg or diastolic blood pressure greater than 80 mmHg or taking medication for the condition (https://ibn.fm/icRSu). Within this category of adults, some fall into a medication-resistant form of hypertension.
A new study by The University of Toledo College of Medicine and Life Sciences has shown that gut bacteria may be a culprit for medication-resistant hypertension, solving an elusive mystery that has plagued many Americans and their physicians. The study, conducted using lab rats, concluded that a specific gut bacterium, Coprococcus, was responsible for breaking down the antihypertension medications quinapril and ramipril, resulting in compromised blood pressure-lowering effects.
The study also cites a specific instance where a female with medication-resistant hypertension was administered antibiotics two weeks prior to a procedure. Her blood pressure lowered naturally – as the antibiotics depleted the gut bacteria. Although long-term antibiotics are not a viable solution for lowering blood pressure, the group has concluded that more research is necessary (https://ibn.fm/Do8tT).
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is on a mission to transform the way hypertension is treated through its patented technology, DehydraTECH(TM). DehydraTECH improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing. DehydraTECH also provides the following benefits:
- Masks unwanted tastes by eliminating the need for sugar-filled edibles
- Improves the speed of onset, with effects felt in minutes
- Increases bioavailability by more effectively delivering the drug into the bloodstream
- Increases brain absorption, with testing suggesting up to 10x improvement
- Reduces drug administration costs with a higher ratio of drug delivery
Lexaria’s ongoing research into DehydraTECH-CBD for the treatment of hypertension was received favorably by the FDA during the company’s pre-Investigational New Drug (pre-IND) meeting. The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway for its program. “We are very pleased to have received comments from the FDA toward opening our IND program. We will be executing FDA-confirmed IND-enabling work immediately,” said John Docherty, President of Lexaria (https://ibn.fm/w6Bva). “We were delighted that our proposals were very well received by the FDA, and the feedback received will be very helpful in compiling and filing our IND application as the next major regulatory step we are focused on moving forward.”
The global antihypertension drug market was valued at $30.2 billion in 2021. This market is expected to grow at a CAGR of 3%, resulting in a valuation of $40 billion by 2031 (https://ibn.fm/5BQdY). The global CBD market was valued at $5.18 billion in 2021 and is expected to grow at a CAGR of 16.8%, resulting in a valuation of $22.05 billion by 2030 (https://ibn.fm/jpju5). Lexaria is leveraging both markets in its current pursuit of hypertension therapies and is positioned to penetrate through the use of its DehydraTECH technology – bringing about viable solutions to solve even the most medication-resistant hypertension through increased bioavailability and absorption of medication for this purpose.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com